Physician profile
Shady Salib
NPI 1245218296
$7,067.45
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $1,605 · 2021: $1,235 · 2022: $1,494 · 2023: $538.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $538.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,224.61 | 2019-2023 | Breztri |
| Novo Nordisk INC | $1,051.14 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $746.34 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $497.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $479.09 | 2019-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $472.18 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $306.90 | 2019-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $288.75 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $212.31 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $161.44 | 2019-2022 | |
| Abbvie INC. | $145.72 | 2021-2023 | Ubrelvy |
| Astellas Pharma US INC | $135.90 | 2019-2020 | |
| Relievant Medsystems, INC. | $135.88 | 2022 | |
| Horizon Therapeutics Plc | $124.71 | 2019-2022 | |
| Amarin Pharma, INC. | $120.73 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $113.36 | 2022 | |
| Abbott Laboratories | $101.18 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $99.04 | 2019-2021 | |
| Amgen INC. | $96.41 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $92.43 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $80.77 | 2022-2023 | Quviviq |
| Allergan, INC. | $77.41 | 2019-2020 | |
| Exact Sciences Corporation | $60.41 | 2023 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $33.02 | 2021 | |
| Boston Scientific Corporation | $31.33 | 2021 | |
| Currax Pharmaceuticals LLC | $27.58 | 2022-2023 | Onzetra Xsail, Contrave |
| Vivus LLC | $23.08 | 2020 | |
| Merck Sharp & Dohme LLC | $19.00 | 2020 | |
| Scynexis, INC. | $18.98 | 2022 | |
| Linus Health, INC. | $17.62 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shady Salib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.